Advances in the treatment of Parkinson's disease

被引：240

作者：

Singh, Neha ^{[1
]}

Pillay, Viness ^{[1
]}

Choonara, Yahya E. ^{[1
]}

机构：

[1] Univ Witwatersrand, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, Gauteng, South Africa

来源：

PROGRESS IN NEUROBIOLOGY | 2007年 / 81卷 / 01期

关键词：

Parkinson's disease (PD); current therapies; neuroprotective; agents; non-pharmacological treatments; drug delivery; levodopa; nicotine; PD vaccine; cell transplantation;

D O I：

10.1016/j.pneurobio.2006.11.009

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Parkinson's disease (PD) affects one in every 100 persons above the age of 65 years, making it the second most common neurodegenerative disease after Alzheimer's disease. PD is a disease of the central nervous system that leads to severe difficulties with body motions. The currently available therapies aim to improve the functional capacity of the patient for as long as possible; however they do not modify the progression of the neurodegenerative process. The need for newer and more effective agents is consequently receiving a great deal of attention and consequently being subjected to extensive re search. This review concisely compiles the limitations of currently available therapies and the most recent research regarding neuroprotective agents, antioxidants, stem cell research, vaccines and various surgical techniques available and being developed for the management of PD. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：29 / 44

页数：16

共 220 条

[81]

KELLY PJ, 1995, THERAPY PARKINSONS D, P331

[82] Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: Implications for Parkinson's disease [J].

Khan, FH ;

Sen, T ;

Maiti, AK ;

Jana, S ;

Chatterjee, U ;

Chakrabarti, S .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1741 (1-2) :65-74

[83] Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy [J].

Klos, KJ ;

Bower, JH ;

Josephs, KA ;

Matsumoto, JY ;

Ahskog, JE .

PARKINSONISM & RELATED DISORDERS, 2005, 11 (06) :381-386

[84] Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2 [J].

Knott, C ;

Stern, G ;

Wilkin, GP .

MOLECULAR AND CELLULAR NEUROSCIENCE, 2000, 16 (06) :724-739

[85]

KOLLER WC, 1990, NEUROLOGY, V40, P40

[86] Trophic effects of selegiline on cultured dopaminergic neurons [J].

Kontkanen, O ;

Castrén, E .

BRAIN RESEARCH, 1999, 829 (1-2) :190-192

[87] DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF DUODENAL INFUSION OF LEVODOPA CARBIDOPA IN PARKINSONS-DISEASE PATIENTS WITH ON-OFF FLUCTUATIONS [J].

KURTH, MC ;

TETRUD, JW ;

TANNER, CM ;

IRWIN, I ;

STEBBINS, GT ;

GOETZ, CG ;

LANGSTON, JW .

NEUROLOGY, 1993, 43 (09) :1698-1703

[88] Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [J].

Lang, AE ;

Gill, S ;

Patel, NK ;

Lozano, A ;

Nutt, JG ;

Penn, R ;

Brooks, DJ ;

Hotton, G ;

Moro, E ;

Heywood, P ;

Brodsky, MA ;

Burchiel, K ;

Kelly, P ;

Dalvi, A ;

Scott, B ;

Stacy, M ;

Turner, D ;

Wooten, VGF ;

Elias, WJ ;

Laws, ER ;

Dhawan, V ;

Stoessl, AJ ;

Matcham, J ;

Coffey, RJ ;

Traub, M .

ANNALS OF NEUROLOGY, 2006, 59 (03) :459-466

[89]

Latchman DS, 2001, REV NEUROSCIENCE, V12, P69

[90] Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease [J].

Lemay, S ;

Chouinard, S ;

Blanchet, P ;

Masson, H ;

Soland, V ;

Beuter, A ;

Bédard, MA .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (01) :31-39

← 4 5 6 7 8 9 10 11 12 13 →